What records are connected here?
- Evidence lanes
- 2
- Source years
- 7
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved2Evidence: Smaller human trialsInflammation and immune
Also called Cathelicidin LL-37, Ropocamptide, LL371
LL-37 is a 37-amino-acid peptide of the human cathelicidin family, recorded in FDA’s substance registry as cathelicidin LL-37 (human), with the international name ropocamptide.1 It has been tested in small randomized trials in chronic leg and foot ulcers. The largest, in 148 people with venous leg ulcers, found no significant difference in healing compared with placebo.6,7,8 FDA lists cathelicidin LL-37 among compounding substances that may present significant safety risks, stating that it lacks enough safety information to know whether LL-37 would cause harm in people, and noting nonclinical findings of harm to male reproduction and tumor promotion.2 No FDA approval is reported in the sources reviewed here, and LL-37 is not among the six peptides in HHS’s October 2026 draft policy.2,4
| What it is | A 37-amino-acid peptide beginning with two leucines (hence LL-37), recorded as human cathelicidin LL-37 and ropocamptide in FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA lists cathelicidin LL-37 among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2 |
| Human evidence | Three small randomized, placebo-controlled trials in chronic ulcers, with mixed results: two reported faster healing, and the largest found no significant difference overall.6,7,8 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
LL-37 is a peptide of 37 amino acids, starting with two leucines, that FDA’s substance registry records as cathelicidin LL-37 (human) and under the international nonproprietary name ropocamptide.1
The company behind the venous leg ulcer trials states that it is developing LL-37 under the name ropocamptide.7
The authors of the 2023 diabetic foot ulcer trial describe LL-37 as having antimicrobial properties and as promoting new blood vessel formation and the movement and growth of skin cells.8
Those are researchers’ descriptions of proposed actions. The FDA sources reviewed here do not describe how LL-37 works, and report nonclinical findings on its possible harms.2,8
In a 2014 first-in-human trial in 34 people with hard-to-heal venous leg ulcers, the two lower LL-37 strengths were reported to speed healing compared with placebo over four weeks, while the highest strength showed no difference. The authors reported no safety concerns.6
HEAL LL-37, a larger randomized, placebo-controlled trial in 148 people with venous leg ulcers published in 2021, did not find a significant difference in healing between LL-37 and placebo in the whole study population. An after-the-fact analysis suggested a benefit in people with large ulcers, which the authors say needs a properly powered trial.7
In a 2023 randomized, double-blind trial in 25 people with mildly infected diabetic foot ulcers, granulation, a measure of wound healing, increased more with LL-37 than with placebo, but inflammation markers and bacterial counts did not fall more.8
ClinicalTrials.gov also lists a study of LL37 in melanoma (NCT02225366), listed as Phase 1/Phase 2 and completed in its December 9, 2021 record. A registration lists what was planned; it does not show whether LL-37 worked.9
FDA states that it lacks sufficient safety-related information on cathelicidin LL-37 to know whether it would cause harm when given to humans.2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of LL-37 by FDA.1,2
FDA’s compounding safety-risk page, current as of April 22, 2026, lists cathelicidin LL-37 among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions and characterization problems.2
FDA’s page for the next meeting of its Pharmacy Compounding Advisory Committee, current as of April 15, 2026, lists cathelicidin LL-37 among substances the committee will discuss for the 503A bulks list at a meeting before the end of February 2027, with the date not yet set.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. LL-37 is not among them.3,4
Whether it helps ulcers heal: the largest trial reviewed here found no significant difference from placebo, and the others were small.6,7,8
Whether it is safe in people, which FDA states it lacks the information to judge, and whether the reproductive and tumor-promoting effects seen in nonclinical research apply to people.2
What FDA’s advisory committee will conclude; its page did not give a meeting date.5
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for LL-37: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for LL-37 are a bounded selection, not every registration or paper about LL-37. For the years before LL-37 was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list LL-37 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name LL-37 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
No FDA approval reported; on FDA’s compounding safety-risk list. Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
No FDA approval reported; on FDA’s compounding safety-risk list. Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date October 31, 2026
Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.↗Added to PeptideScanner November 15, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT02225366↗Source date December 9, 2021Literature metadata · added November 15, 2026
Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.↗Source date October 31, 2026Literature metadata · added November 15, 2026
Antibiofilm properties of cathelicidin LL-37: an in-depth review.↗Source date October 30, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.
PeptideScanner retained ClinicalTrials.gov record NCT02225366 at 2026-11-16T16:10:17.145Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was ll-37.
PubMed lists PMID 23931055 in Periodontology 2000 as Journal Article, Research Support, N.I.H., Extramural, Review, with publication-date metadata of 2013-10 (month precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span September 28, 2020 to October 31, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 38057654 in World journal of microbiology & biotechnology as Journal Article, Review, with publication-date metadata of 2023-12-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36781570 in World journal of microbiology & biotechnology as Review, Journal Article, with publication-date metadata of 2023-02-14 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42861262 in Clinical, cosmetic and investigational dermatology as Journal Article, Review, with publication-date metadata of 2026-10-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42095322 in Immunity, inflammation and disease as Journal Article, Review, with publication-date metadata of 2026-05 (month precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 38540740 in Biomolecules as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-03-08 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37919905 in Biophysical journal as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41270816 in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases as Journal Article, Review, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40960088 in Archivum immunologiae et therapiae experimentalis as Journal Article, Review, with publication-date metadata of 2025-09-07 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 40869425 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2025-08-21 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39954662 in International immunopharmacology as Journal Article, Review, with publication-date metadata of 2025-02-15 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39615616 in Pharmacological research as Journal Article, Review, with publication-date metadata of 2024-11-28 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39643165 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2024-12-04 (day precision). PeptideScanner associated the retained record with the identity slug ll-37. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
Wound Repair and Regeneration · Official source · Source checked November 16, 2026
Wound Repair and Regeneration · Official source · Source checked November 16, 2026
Archives of Dermatological Research · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026